NEW YORK, NY--(Marketwire - 07/12/11) - Cancer is projected to become the leading cause of death worldwide this year by the World Health Organization, and has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the Healthcare Sector and provides equity research on Dendreon Corporation (NASDAQ:DNDN - News) and ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX - News). Access to the full company reports can be found at:www.bedfordreport.com/DNDNwww.bedfordreport.com/ANXCancer medication is also an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards, recommending that sponsors generally be required to conduct randomized trials rather than single-arm studies, and that there be more extensive postmarketing studies to confirm clinical benefit.The Bedford Report releases investment research on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.Dendreon Corporation engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. Dendreon's first product, PROVENGE, was approved by the FDA in April 2010. Recently, the company announced that the Centers for Medicare and Medicaid Services (CMS) has agreed to fully reimburse Provenge.ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. One of the company's lead product candidates is Exelbine and ANX-514 -- a novel emulsion formulation of currently marketed chemotherapy drugs.The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer.
The Bedford Report